These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8493423)

  • 61. Research ethics. NIH examines standards for consent.
    Marshall E
    Science; 1998 Jun; 280(5370):1688. PubMed ID: 9660706
    [No Abstract]   [Full Text] [Related]  

  • 62. NCI announces plan to overhaul clinical-trials system.
    Miller JL
    Am J Health Syst Pharm; 2000 Jul; 57(13):1202. PubMed ID: 10902058
    [No Abstract]   [Full Text] [Related]  

  • 63. Independence of the statistician who analyses unblinded data.
    Siegel JP; O'Neill RT; Temple R; Campbell G; Foulkes MA
    Stat Med; 2004 May; 23(10):1527-9. PubMed ID: 15122732
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Health-related quality of life and symptom management research sponsored by the National Cancer Institute.
    Minasian LM; O'Mara AM; Reeve BB; Denicoff AM; Kelaghan J; Rowland JH; Trimble EL;
    J Clin Oncol; 2007 Nov; 25(32):5128-32. PubMed ID: 17991932
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Oversight mechanisms for clinical research.
    Snyderman R; Holmes EW
    Science; 2000 Jan; 287(5453):595-7. PubMed ID: 10691540
    [No Abstract]   [Full Text] [Related]  

  • 66. Surrogate End Points and Their Validation in Oncology Clinical Trials.
    Zhao F
    J Clin Oncol; 2016 May; 34(13):1436-7. PubMed ID: 26951314
    [No Abstract]   [Full Text] [Related]  

  • 67. Playing safe and preserving integrity: making the FDA model work.
    Wittes J
    Stat Med; 2004 May; 23(10):1523-5. PubMed ID: 15122731
    [TBL] [Abstract][Full Text] [Related]  

  • 68. IRBs search for answers and support during a time of institutional change.
    Phillips DF
    JAMA; 2000 Feb; 283(6):729-30. PubMed ID: 10683041
    [No Abstract]   [Full Text] [Related]  

  • 69. The case against independent monitoring committees.
    Harrington D; Crowley J; George SL; Pajak T; Redmond C; Wieand S
    Stat Med; 1994 Jul 15-30; 13(13-14):1411-4. PubMed ID: 7973220
    [No Abstract]   [Full Text] [Related]  

  • 70. NIH Recombinant DNA Advisory Committee data management report. June 18-19, 1998.
    Hum Gene Ther; 1998 Sep; 9(14):2143-61. PubMed ID: 9759940
    [No Abstract]   [Full Text] [Related]  

  • 71. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it.
    O'Neill RT; Temple R
    Clin Pharmacol Ther; 2012 Mar; 91(3):550-4. PubMed ID: 22318615
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Growing pains: central review board project still developing.
    Randal J
    J Natl Cancer Inst; 2003 May; 95(9):636-7. PubMed ID: 12734305
    [No Abstract]   [Full Text] [Related]  

  • 73. Scientific review of EORTC trials: the functioning of the New Treatment Committee and Protocol Review Committee.
    Lardot C; Steward W; Van Glabbeke M; Armand JP
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S24-30. PubMed ID: 11858960
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The independent statistician model: How well is it working?
    DeMets D
    Clin Trials; 2018 Aug; 15(4):329-334. PubMed ID: 29741390
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Interim analyses in clinical trials: why do we plan them?
    Fossâ SD; Skovlund E
    J Clin Oncol; 2000 Dec; 18(24):4007-8. PubMed ID: 11118460
    [No Abstract]   [Full Text] [Related]  

  • 76. Ecological analysis of the first generation of community clinical oncology programs.
    Schopler JH
    Health Serv Res; 1993 Apr; 28(1):69-95. PubMed ID: 8463110
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Breast cancer: clearing trails in the forest without losing our way.
    Lancet; 1994 Apr; 343(8905):1049-50. PubMed ID: 7909092
    [No Abstract]   [Full Text] [Related]  

  • 78. NIH Recombinant DNA Advisory Committee data management report. March 12, 1999.
    Hum Gene Ther; 1999 Jun; 10(9):1577-89. PubMed ID: 10395382
    [No Abstract]   [Full Text] [Related]  

  • 79. Early stopping, interim analyses, and monitoring committees: what are the tradeoffs?
    Zelen M
    J Clin Oncol; 1987 Sep; 5(9):1314-5. PubMed ID: 3625252
    [No Abstract]   [Full Text] [Related]  

  • 80. Duke's hazards. Did medical experiments put patients needlessly at risk?
    Kaplan S; Brownlee S
    US News World Rep; 1999 May; 126(20):66-8, 70. PubMed ID: 10387890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.